PROK vs. APGE, AMPH, TARS, IOVA, IRON, IBRX, WVE, BLTE, GLPG, and ARQT
Should you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Apogee Therapeutics (APGE), Amphastar Pharmaceuticals (AMPH), Tarsus Pharmaceuticals (TARS), Iovance Biotherapeutics (IOVA), Disc Medicine (IRON), ImmunityBio (IBRX), Wave Life Sciences (WVE), Belite Bio (BLTE), Galapagos (GLPG), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry.
ProKidney vs.
Apogee Therapeutics (NASDAQ:APGE) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends.
Apogee Therapeutics has a beta of 2.26, meaning that its stock price is 126% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
Apogee Therapeutics received 16 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 100.00% of users gave Apogee Therapeutics an outperform vote while only 57.14% of users gave ProKidney an outperform vote.
79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 36.1% of Apogee Therapeutics shares are owned by insiders. Comparatively, 41.5% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Apogee Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.
ProKidney's return on equity of 0.00% beat Apogee Therapeutics' return on equity.
Apogee Therapeutics presently has a consensus price target of $89.71, suggesting a potential upside of 142.08%. ProKidney has a consensus price target of $4.50, suggesting a potential upside of 171.08%. Given ProKidney's higher probable upside, analysts plainly believe ProKidney is more favorable than Apogee Therapeutics.
In the previous week, ProKidney had 1 more articles in the media than Apogee Therapeutics. MarketBeat recorded 2 mentions for ProKidney and 1 mentions for Apogee Therapeutics. ProKidney's average media sentiment score of 0.64 beat Apogee Therapeutics' score of 0.15 indicating that ProKidney is being referred to more favorably in the news media.
Summary
ProKidney beats Apogee Therapeutics on 9 of the 15 factors compared between the two stocks.
Get ProKidney News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProKidney Competitors List
Related Companies and Tools
This page (NASDAQ:PROK) was last updated on 1/21/2025 by MarketBeat.com Staff
Free PROK Stock Alerts